PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as ...

Exclusive: Fears that US companies may withdraw more medicines as global markets react to policy changes by the Trump administration ...

A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". SLOUGH, England and RICHMOND, Va., March 7, 2019 /PRNewswire/ -- Indivior ...

RICHMOND, Va. and SLOUGH, England, Nov. 30, 2017 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that the U.S. Food and Drug Administration (FDA) has approved SUBLOCADE TM (buprenorphine ...

Add Yahoo as a preferred source to see more of our stories on Google. Dr. Andrew Herring, who works in the addiction clinic at Highland Hospital in Oakland, Calif., says that Sublocade, an injectable ...

SUBLOCADE use during pregnancy showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates RICHMOND, Va., May 1, 2025 /PRNewswire/ -- ...

Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.

Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm ...

INDV's Sublocade reaches 500,000+ U.S. patients. Management expects faster 2026 growth through cost optimization and strong execution.

The Food & Drug Administration (FDA) announced its approval of an injectable form of buprenorphine (brand name: Sublocade), a medication used to treat opiate addiction. Sublocade releases a steady ...

OAKLAND — Dr. Andrew Herring has a clear goal walking into every appointment with patients seeking medication to treat an opioid use disorder: persuade them to get an injection of extended-release ...

The Food & Drug Administration (FDA) announced its approval of an injectable form of buprenorphine (brand name: Sublocade), a medication used to treat opiate addiction. Sublocade releases a steady ...